STXS

Stereotaxis, Inc. 10-Q Summary (Period Ended June 30, 2008)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., an accelerated filer, for the period ended June 30, 2008. The company designs, manufactures, and markets the NIOBE magnetic navigation system and ODYSSEY information management system for interventional cardiology procedures. As of July 31, 2008, there were 37,446,645 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 4% year-over-year for the six-month period, driven by a 35% increase in disposables, service, and accessories revenue. System revenue decreased 5% due to lower average selling prices despite higher unit sales (12 NIOBE and 6 ODYSSEY systems sold vs. 11 NIOBE systems in 2007).
• Cost of Revenue: Total cost of revenue decreased 13% to $6.6 million. This improvement was largely due to the absence of a $1.9 million inventory impairment charge recorded in the prior year for first-generation NIOBE systems.
• Operating Expenses: Research and Development (R&D) expenses decreased 26% to $9.5 million due to reduced new product introduction costs. Conversely, Sales and Marketing expenses increased 25% to $16.3 million, and General and Administrative expenses increased 10% to $10.7 million, reflecting expanded operations in Europe.
• Liquidity and Debt: Total debt increased significantly from approximately $7.0 million to $20.6 million. This includes a $10 million draw on the revolving credit facility and new term notes. Working capital declined sharply from $21.9 million to $1.9 million as cash was utilized to fund operations and debt was increased.

Guidance, Outlook, Risks, and Unusual Items

• Cash Flow Outlook: Management expects negative cash flow from operations for the next 12 months. The company anticipates funding operations through existing cash, the recent $10 million advance from Biosense Webster (subsequent event), and available credit lines.
• Subsequent Event (Biosense Webster): On July 18, 2008, the company received a $10 million advance from Biosense Webster against future revenue share amounts. This amount is to be recouped from future revenue shares or via supplemental payments starting May 2010.
• Investment Impairment: The company recorded a $32,000 "other-than-temporary" impairment charge on $500,000 of auction rate securities (ARS) due to liquidity issues in the credit markets. These securities are now classified as long-term investments.
• Risk Factors:
  • Catheter Issue: Commercialization of the magnetic irrigated catheter was halted in March 2008 due to char/coagulum formation. A PMA supplement was filed in July 2008, with a target for European re-launch in Q4 2008 and U.S. re-launch in 2009. Delays could adversely affect operations.
  • Liquidity Risk: The company relies on renewing its bank facility (maturing March 2009) and may require additional financing, which could be dilutive.
  • Market Risk: Exposure to foreign currency fluctuations (Euro) and interest rate changes on investments and borrowings.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the "tangible net worth" covenant ($5 million minimum) and other financial covenants under the amended credit agreement.
• Catheter Regulatory Status: Monitor the status of the PMA supplement and CE Mark filing for the magnetic irrigated catheter to assess the timeline for revenue recovery from this product line.
• Liquidity Runway: Confirm the sufficiency of the $11.4 million cash balance plus the $10 million Biosense advance to cover operating losses through the renewal of the March 2009 credit facility.
• Auction Rate Securities: Assess the potential for further impairment on the remaining $469,392 of long-term auction rate securities if market liquidity does not improve.
• Revenue Recognition: Review the backlog of $72 million for systems to understand the timing of future revenue recognition, noting that some orders are subject to contingencies.